Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.48 |
| ▸ | BTK | Q06187 | 2/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | HRH1 | P35367 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.42 |
| ▸ | GNRHR | P30968 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2098108 | 1.00 | DPP4 (0.48) | DPP4BTKMAP4K4CYP2D6HRH1 | |
| SCHEMBL2097778 | 0.94 | DPP4 (0.49) | DPP4BTKMAP4K4CYP2D6HRH1 | |
| SCHEMBL2097781 | 0.94 | DPP4 (0.49) | DPP4BTKMAP4K4CYP2D6HRH1 | |
| SCHEMBL3149955 | 0.88 | DPP4 (0.47) | DPP4BTKMAP4K4CYP2D6HRH1 | |
| SCHEMBL2098878 | 0.87 | DPP4 (0.50) | DPP4BTKMAP4K4CYP2D6HRH1 | |
| SCHEMBL2098876 | 0.87 | DPP4 (0.50) | DPP4BTKMAP4K4CYP2D6HRH1 | |
| SCHEMBL3145390 | 0.84 | DPP4 (0.48) | DPP4BTKMAP4K4CYP2D6HRH1 | |
| SCHEMBL3150575 | 0.83 | DPP4 (0.49) | DPP4BTKMAP4K4CYP2D6HRH1 | |
| SCHEMBL2098253 | 0.83 | MAPT (0.47) | DPP4BTKMAP4K4JAK3PADI4 | |
| SCHEMBL29668368 | 0.78 | DPP4 (0.53) | DPP4BTKMAP4K4JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163774-B2 | Antidiabetic agents; 2-(amino-substituted piperidin-1-yl)benzimidazoles; N-(4-Chlorobenzyl)-2-(3-aminopiperidin-1-yl)-1-(4-fluorobenzyl)-1H-benzimidazole-6-carboxamide hydrochloride for example; use in combination with other antidiabetic, antilipemic agents | SANOFI-AVENTIS (FR) | 2012-04-24 | — | — | US | disclosed |
| US-20080090868-A1 | AMIDE-SUBSTITUTED 8 N BENZIMIDAZOLES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090868-A1 | AMIDE-SUBSTITUTED 8 N BENZIMIDAZOLES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS | DPP8, GPR119, ABAT | DPP4 10/4885BTK 1231/4885MAP4K4 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.